NORTHRIDGE, CA and CAMBRIDGE, UK--(Marketwired - Oct 9, 2013) - Regenerative medicine company Avita Medical Ltd. (
The Company will be presenting in Track 1 at 11:30 AM on Monday, October 14th as part of the conference's 3rd Annual Regen Med Partnering Forum. Presentation will be live-streamed on the day of the program.
"We are pleased to be presenting at this leading regenerative medicine industry conference," said Dr. William Dolphin, Avita Medical's CEO. "ReCell® Spray‐On Skin® is on the market in other countries and undergoing FDA clinical trials in the US. This conference is a great venue to generate awareness among potential corporate partners and institutional investors as we approach FDA submission."
This is a three-day conference organized annually by the Alliance for Regenerative Medicine, the California Institute for Regenerative Medicine and the Sanford Consortium for Regenerative Medicine with the intention of bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. For more information on the conference: http://stemcellmeetingonthemesa.com/
ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com) develops and distributes regenerative and tissue‐engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue‐culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray‐On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE‐marked for Europe, TGA‐registered in Australia, and SFDA‐cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.